73 related articles for article (PubMed ID: 38658567)
1. Pharmacologic Targeting of Histone H3K27 Acetylation/BRD4-dependent Induction of ALDH1A3 for Early-phase Drug Tolerance of Gastric Cancer.
Lee J; Mashima T; Kawata N; Yamamoto N; Morino S; Inaba S; Nakamura A; Kumagai K; Wakatsuki T; Takeuchi K; Yamaguchi K; Seimiya H
Cancer Res Commun; 2024 May; 4(5):1307-1320. PubMed ID: 38669046
[TBL] [Abstract][Full Text] [Related]
2. BNC2 is a putative tumor suppressor gene in high-grade serous ovarian carcinoma and impacts cell survival after oxidative stress.
Cesaratto L; Grisard E; Coan M; Zandonà L; De Mattia E; Poletto E; Cecchin E; Puglisi F; Canzonieri V; Mucignat MT; Zucchetto A; Stocco G; Colombatti A; Nicoloso MS; Spizzo R
Cell Death Dis; 2016 Sep; 7(9):e2374. PubMed ID: 27899818
[TBL] [Abstract][Full Text] [Related]
3. 5-Hydroxymethylcytosine signals in serum are a predictor of chemoresistance in high-grade serous ovarian cancer.
Weigert M; Cui XL; West-Szymanski D; Yu X; Bilecz AJ; Zhang Z; Dhir R; Kehoe M; Zhang W; He C; Lengyel E
Gynecol Oncol; 2024 Mar; 182():82-90. PubMed ID: 38262243
[TBL] [Abstract][Full Text] [Related]
4. Single-cell and spatial transcriptome sequencing uncover a platinum-resistant cluster overexpressed TACSTD2 in high-grade serous ovarian cancer.
Han X; Gao Y; Jiang M; Li Z; Guo J; Li Y; Yi J; Hou L; Cheng J; Feng L; Jin Y; Zhao X; Yue W
J Cancer; 2024; 15(11):3427-3440. PubMed ID: 38817863
[No Abstract] [Full Text] [Related]
5. Studying platinum sensitivity and resistance in high-grade serous ovarian cancer: Different models for different questions.
Alkema NG; Wisman GB; van der Zee AG; van Vugt MA; de Jong S
Drug Resist Updat; 2016 Jan; 24():55-69. PubMed ID: 26830315
[TBL] [Abstract][Full Text] [Related]
6. The role of distinct BRD4 isoforms and their contribution to high-grade serous ovarian carcinoma pathogenesis.
Drumond-Bock AL; Bieniasz M
Mol Cancer; 2021 Nov; 20(1):145. PubMed ID: 34758842
[TBL] [Abstract][Full Text] [Related]
7. ATF3 characterizes aggressive drug-tolerant persister cells in HGSOC.
Böpple K; Oren Y; Henry WS; Dong M; Weller S; Thiel J; Kleih M; Gaißler A; Zipperer D; Kopp HG; Aylon Y; Oren M; Essmann F; Liang C; Aulitzky WE
Cell Death Dis; 2024 Apr; 15(4):290. PubMed ID: 38658567
[TBL] [Abstract][Full Text] [Related]
8. Platinum-resistance in epithelial ovarian cancer: an interplay of epithelial-mesenchymal transition interlinked with reprogrammed metabolism.
Leung D; Price ZK; Lokman NA; Wang W; Goonetilleke L; Kadife E; Oehler MK; Ricciardelli C; Kannourakis G; Ahmed N
J Transl Med; 2022 Dec; 20(1):556. PubMed ID: 36463238
[TBL] [Abstract][Full Text] [Related]
9. Frizzled-7 Identifies Platinum-Tolerant Ovarian Cancer Cells Susceptible to Ferroptosis.
Wang Y; Zhao G; Condello S; Huang H; Cardenas H; Tanner EJ; Wei J; Ji Y; Li J; Tan Y; Davuluri RV; Peter ME; Cheng JX; Matei D
Cancer Res; 2021 Jan; 81(2):384-399. PubMed ID: 33172933
[TBL] [Abstract][Full Text] [Related]
10. Fn14 overcomes cisplatin resistance of high-grade serous ovarian cancer by promoting Mdm2-mediated p53-R248Q ubiquitination and degradation.
Wu AY; Gu LY; Cang W; Cheng MX; Wang WJ; Di W; Huang L; Qiu LH
J Exp Clin Cancer Res; 2019 Apr; 38(1):176. PubMed ID: 31023317
[TBL] [Abstract][Full Text] [Related]
11. Epithelial/mesenchymal heterogeneity of high-grade serous ovarian carcinoma samples correlates with miRNA let-7 levels and predicts tumor growth and metastasis.
Chirshev E; Hojo N; Bertucci A; Sanderman L; Nguyen A; Wang H; Suzuki T; Brito E; Martinez SR; Castañón C; Mirshahidi S; Vazquez ME; Wat P; Oberg KC; Ioffe YJ; Unternaehrer JJ
Mol Oncol; 2020 Nov; 14(11):2796-2813. PubMed ID: 32652647
[TBL] [Abstract][Full Text] [Related]
12. PTPN13 Participates in the Regulation of Epithelial-Mesenchymal Transition and Platinum Sensitivity in High-Grade Serous Ovarian Carcinoma Cells.
Aptecar L; Puech C; Lopez-Crapez E; Peter M; Coopman P; D'Hondt V; Freiss G
Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37895093
[TBL] [Abstract][Full Text] [Related]
13. Disrupting cellular memory to overcome drug resistance.
Harmange G; Hueros RAR; Schaff DL; Emert B; Saint-Antoine M; Kim LC; Niu Z; Nellore S; Fane ME; Alicea GM; Weeraratna AT; Simon MC; Singh A; Shaffer SM
Nat Commun; 2023 Nov; 14(1):7130. PubMed ID: 37932277
[TBL] [Abstract][Full Text] [Related]
14. Diverse clonal fates emerge upon drug treatment of homogeneous cancer cells.
Goyal Y; Busch GT; Pillai M; Li J; Boe RH; Grody EI; Chelvanambi M; Dardani IP; Emert B; Bodkin N; Braun J; Fingerman D; Kaur A; Jain N; Ravindran PT; Mellis IA; Kiani K; Alicea GM; Fane ME; Ahmed SS; Li H; Chen Y; Chai C; Kaster J; Witt RG; Lazcano R; Ingram DR; Johnson SB; Wani K; Dunagin MC; Lazar AJ; Weeraratna AT; Wargo JA; Herlyn M; Raj A
Nature; 2023 Aug; 620(7974):651-659. PubMed ID: 37468627
[TBL] [Abstract][Full Text] [Related]
15. Adaptive transcriptomic and immune infiltrate responses in the tumor immune microenvironment following neoadjuvant chemotherapy in high grade serous ovarian cancer reveal novel prognostic associations and activation of pro-tumorigenic pathways.
James NE; Woodman M; De La Cruz P; Eurich K; Ozsoy MA; Schorl C; Hanley LC; Ribeiro JR
Front Immunol; 2022; 13():965331. PubMed ID: 36131935
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
